Vertice launches THYQUIDITY™ (levothyroxine sodium) Oral Sol
Feb 24, 2021 9:49:46 GMT -5
sla55, prcgorman2, and 3 more like this
Post by wyattdog on Feb 24, 2021 9:49:46 GMT -5
NEW PROVIDENCE, N.J., Feb. 24, 2021 /PRNewswire/ -- Vertice Pharma ("Vertice"), a specialty pharmaceuticals company focused on improving patients' health, today announced the launch of THYQUIDITY. THYQUIDITY is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.*
THYQUIDITY is a liquid dosage form of levothyroxine administered by a calibrated oral syringe, and is designed to deliver individualized dosing for patients. THYQUIDITY is a liquid oral solution of levothyroxine sodium containing 100 mcg per 5 mL (20 mcg per mL), and it is supplied in a package of two 100 mL bottles. THYQUIDITY offers broad dosing flexibility for patients, as well as consistent daily dosing.
"The launch of THYQUIDITY marks our first branded pharmaceutical prescription product and reflects our ongoing mission to deliver high-quality and affordable pharmaceutical products for patients. Vertice is committed to providing branded and specialty generics products and we look forward to building off the momentum of today's launch," said Scott Meyers, Chief Executive Officer of Vertice Pharma.
Vertice's co-promotion partner is MannKind Corporation (Nasdaq: MNKD). MannKind's sales force will promote THYQUIDITY to adult and pediatric endocrinologists and other U.S. healthcare providers who treat hypothyroidism.
"THYQUIDITY fits nicely into our product portfolio of branded and specialty generics and is an exciting launch for the team at Vertice. As we continue to evaluate select opportunities to bring products to market, we are proud to have partnered with MannKind in the launch of this important product," said John Walsh, Head of Specialty Sales and Marketing at Vertice Pharma.
Hypothyroidism, also called underactive thyroid disease, is a common disorder in which the thyroid gland does not produce enough thyroid hormone to meet the needs of the body. The prevalence of hypothyroidism is 4.6% in the US population.1 Symptoms include fatigue, lethargy, cold intolerance, weight gain, constipation, change in voice, and dry skin.2 Most patients require lifelong therapy to treat their hypothyroidism.3
Vertice Pharma was founded in 2015 with a unique focus on acquiring specialty pharmaceutical companies and products, including both branded and generic products, to create a durable specialty pharmaceutical business of scale.
Patient Use and Important Safety Information
THYQUIDITY is a liquid dosage form of levothyroxine administered by a calibrated oral syringe, and is designed to deliver individualized dosing for patients. THYQUIDITY is a liquid oral solution of levothyroxine sodium containing 100 mcg per 5 mL (20 mcg per mL), and it is supplied in a package of two 100 mL bottles. THYQUIDITY offers broad dosing flexibility for patients, as well as consistent daily dosing.
"The launch of THYQUIDITY marks our first branded pharmaceutical prescription product and reflects our ongoing mission to deliver high-quality and affordable pharmaceutical products for patients. Vertice is committed to providing branded and specialty generics products and we look forward to building off the momentum of today's launch," said Scott Meyers, Chief Executive Officer of Vertice Pharma.
Vertice's co-promotion partner is MannKind Corporation (Nasdaq: MNKD). MannKind's sales force will promote THYQUIDITY to adult and pediatric endocrinologists and other U.S. healthcare providers who treat hypothyroidism.
"THYQUIDITY fits nicely into our product portfolio of branded and specialty generics and is an exciting launch for the team at Vertice. As we continue to evaluate select opportunities to bring products to market, we are proud to have partnered with MannKind in the launch of this important product," said John Walsh, Head of Specialty Sales and Marketing at Vertice Pharma.
Hypothyroidism, also called underactive thyroid disease, is a common disorder in which the thyroid gland does not produce enough thyroid hormone to meet the needs of the body. The prevalence of hypothyroidism is 4.6% in the US population.1 Symptoms include fatigue, lethargy, cold intolerance, weight gain, constipation, change in voice, and dry skin.2 Most patients require lifelong therapy to treat their hypothyroidism.3
Vertice Pharma was founded in 2015 with a unique focus on acquiring specialty pharmaceutical companies and products, including both branded and generic products, to create a durable specialty pharmaceutical business of scale.
Patient Use and Important Safety Information
